trazodone has been researched along with Psychomotor Agitation in 19 studies
Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)
trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.
Psychomotor Agitation: A feeling of restlessness associated with increased motor activity. This may occur as a manifestation of nervous system drug toxicity or other conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The authors compared the efficacy and side effects of trazodone and haloperidol for treating agitated behaviors associated with dementia." | 9.08 | A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. ( Berisford, MA; Gray, KF; Gunay, I; Mahler, ME; Sultzer, DL, 1997) |
| "To determine the clinical efficacy and safety of trazodone, for any type of behavioural or psychological cognition in people with dementia without an additional diagnosis of depression." | 8.82 | Trazodone for agitation in dementia. ( Fioravanti, M; Grimley, EJ; Martinon-Torres, G, 2004) |
| "Antidepressant-induced jitteriness/anxiety syndrome is characterized as anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, and (hypo)mania, which appear immediately after initiation or increased dosage of an antidepressant." | 5.91 | Jitteriness/anxiety syndrome caused by coadministration of celecoxib, a selective COX-2 inhibitor, with escitalopram and trazodone in a patient with depression and spondylolisthesis. ( Kanno, M; Noto, K; Shirata, T; Suzuki, A; Yano, S, 2023) |
| "Trazodone is a multifunctional triazolopyridine drug with antidepressant, anxiolytic, sedative, and hypnotic properties." | 5.48 | Clinical effectiveness of parenteral trazodone for the management of psychomotor activation in patients with bipolar disorder. ( Ballerio, M; Crapanzano, C; Cuomo, A; Emanuele, E; Fagiolini, A; Goracci, A; Politi, P, 2018) |
| "The authors compared the efficacy and side effects of trazodone and haloperidol for treating agitated behaviors associated with dementia." | 5.08 | A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. ( Berisford, MA; Gray, KF; Gunay, I; Mahler, ME; Sultzer, DL, 1997) |
| "Randomized, controlled trials of antidepressants (selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, trazodone, and other antidepressants), compared to either placebo or comparator medications (typical or atypical antipsychotics, anticonvulsants, benzodiazepines, cholinesterase inhibitors, memantine or other medications) for treatment of agitation or psychosis in older adults with dementia." | 4.87 | Antidepressants for agitation and psychosis in dementia. ( Adunuri, N; Gill, SS; Gruneir, A; Herrmann, N; Rochon, P; Seitz, DP, 2011) |
| "To determine the clinical efficacy and safety of trazodone, for any type of behavioural or psychological cognition in people with dementia without an additional diagnosis of depression." | 4.82 | Trazodone for agitation in dementia. ( Fioravanti, M; Grimley, EJ; Martinon-Torres, G, 2004) |
| "Antidepressant-induced jitteriness/anxiety syndrome is characterized as anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, and (hypo)mania, which appear immediately after initiation or increased dosage of an antidepressant." | 1.91 | Jitteriness/anxiety syndrome caused by coadministration of celecoxib, a selective COX-2 inhibitor, with escitalopram and trazodone in a patient with depression and spondylolisthesis. ( Kanno, M; Noto, K; Shirata, T; Suzuki, A; Yano, S, 2023) |
| "Linezolid was discontinued after 5 days and the patient's symptoms resolved." | 1.48 | Linezolid-associated serotonin toxicity after escitalopram discontinuation: concomitant drug considerations. ( Ebied, A; Khoury, A; Penny, ES; Runnstrom, M, 2018) |
| "Trazodone is a multifunctional triazolopyridine drug with antidepressant, anxiolytic, sedative, and hypnotic properties." | 1.48 | Clinical effectiveness of parenteral trazodone for the management of psychomotor activation in patients with bipolar disorder. ( Ballerio, M; Crapanzano, C; Cuomo, A; Emanuele, E; Fagiolini, A; Goracci, A; Politi, P, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (10.53) | 18.7374 |
| 1990's | 5 (26.32) | 18.2507 |
| 2000's | 6 (31.58) | 29.6817 |
| 2010's | 5 (26.32) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Shirata, T | 1 |
| Yano, S | 1 |
| Noto, K | 1 |
| Kanno, M | 1 |
| Suzuki, A | 1 |
| Khoury, A | 1 |
| Runnstrom, M | 1 |
| Ebied, A | 1 |
| Penny, ES | 1 |
| Ballerio, M | 1 |
| Politi, P | 1 |
| Crapanzano, C | 1 |
| Emanuele, E | 1 |
| Cuomo, A | 1 |
| Goracci, A | 1 |
| Fagiolini, A | 1 |
| Osváth, P | 1 |
| Cooper, CM | 1 |
| Baron, JM | 1 |
| Flanagan, SR | 1 |
| Elovic, EP | 1 |
| Sandel, E | 1 |
| Seitz, DP | 1 |
| Adunuri, N | 1 |
| Gill, SS | 1 |
| Gruneir, A | 1 |
| Herrmann, N | 1 |
| Rochon, P | 1 |
| Martinon-Torres, G | 1 |
| Fioravanti, M | 1 |
| Grimley, EJ | 1 |
| Cummings, JL | 1 |
| Tractenberg, RE | 3 |
| Gamst, A | 2 |
| Teri, L | 3 |
| Masterman, D | 1 |
| Thal, LJ | 3 |
| Mintzer, JE | 1 |
| Brawman-Mintzer, O | 1 |
| Tariot, PN | 1 |
| Sultzer, DL | 1 |
| Gray, KF | 1 |
| Gunay, I | 1 |
| Berisford, MA | 1 |
| Mahler, ME | 1 |
| Verma, SD | 1 |
| Davidoff, DA | 1 |
| Kambhampati, KK | 1 |
| Logsdon, RG | 1 |
| Peskind, E | 1 |
| Raskind, M | 1 |
| Weiner, MF | 2 |
| Foster, NL | 1 |
| Schneider, LS | 1 |
| Sano, M | 2 |
| Whitehouse, P | 1 |
| Tariot, P | 1 |
| Mellow, AM | 1 |
| Auchus, AP | 1 |
| Grundman, M | 1 |
| Thomas, RG | 1 |
| Schafer, K | 1 |
| Rosati, DL | 1 |
| Logsdon, R | 1 |
| Galasko, D | 1 |
| Thomas, R | 1 |
| Hottin, P | 1 |
| Eimer, M | 1 |
| Simpson, DM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000179] | Phase 3 | 0 participants | Interventional | Completed | |||
| Utility of Amantadine Hydrochloride in the Treatment of Post-traumatic Irritability: A Randomized, Double-Blind, Placebo-Controlled Trial[NCT00627250] | 76 participants (Actual) | Interventional | 2003-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for trazodone and Psychomotor Agitation
| Article | Year |
|---|---|
[Current treatment of depression and agitation in the elderly -- clinical use of trazodone].
Topics: Aged; Aged, 80 and over; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents, Second-G | 2013 |
Antidepressants for agitation and psychosis in dementia.
Topics: Adult; Antidepressive Agents; Citalopram; Dementia; Humans; Psychomotor Agitation; Psychotic Disorde | 2011 |
Trazodone for agitation in dementia.
Topics: Antidepressive Agents, Second-Generation; Dementia; Humans; Psychomotor Agitation; Selective Seroton | 2004 |
Agitation as a possible expression of generalized anxiety disorder in demented elderly patients: toward a treatment approach.
Topics: Aged; Aggression; Antipsychotic Agents; Anxiety Disorders; Behavior Therapy; Buspirone; Carbamazepin | 1996 |
Treatment strategies for agitation and psychosis in dementia.
Topics: Aged; Anti-Anxiety Agents; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Clozapine; | 1996 |
Management of the agitated elderly patient in the nursing home: the role of the atypical antipsychotics.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Anxiety Agents; Anticonvulsants; Antidepressive Agents; Anti | 1998 |
Management of the behavioral symptoms associated with dementia.
Topics: Aged; Aggression; Antipsychotic Agents; Dementia; Humans; Pindolol; Propranolol; Psychomotor Agitati | 1989 |
3 trials available for trazodone and Psychomotor Agitation
| Article | Year |
|---|---|
A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Dementia; D | 1997 |
Treatment of agitation in AD: a randomized, placebo-controlled clinical trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Behavior Therapy; Double-Blind Method; Female; Haloperid | 2000 |
No long-term effect of behavioral treatment on psychotropic drug use for agitation in Alzheimer's disease patients.
Topics: Aged; Alzheimer Disease; Anti-Anxiety Agents; Antipsychotic Agents; Behavior Therapy; Caregivers; Fe | 2002 |
9 other studies available for trazodone and Psychomotor Agitation
| Article | Year |
|---|---|
Jitteriness/anxiety syndrome caused by coadministration of celecoxib, a selective COX-2 inhibitor, with escitalopram and trazodone in a patient with depression and spondylolisthesis.
Topics: Antidepressive Agents; Anxiety; Celecoxib; Cyclooxygenase 2 Inhibitors; Escitalopram; Female; Humans | 2023 |
Linezolid-associated serotonin toxicity after escitalopram discontinuation: concomitant drug considerations.
Topics: Aged; Anti-Anxiety Agents; Anti-Bacterial Agents; Citalopram; Diagnosis, Differential; Drug Interact | 2018 |
Clinical effectiveness of parenteral trazodone for the management of psychomotor activation in patients with bipolar disorder.
Topics: Adult; Aged; Bipolar Disorder; Female; Humans; Injections, Intramuscular; Injections, Intravenous; L | 2018 |
Case records of the Massachusetts General Hospital. Case 4-2015. A 49-year-old man with obtundation followed by agitation and acidosis.
Topics: Acidosis; Calcium Oxalate; Chromatography, High Pressure Liquid; Consciousness Disorders; Diagnosis, | 2015 |
Managing agitation associated with traumatic brain injury: behavioral versus pharmacologic interventions?
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Behavior Control; Brain Injuries; Dibenzothiazepines; | 2009 |
Regression to the mean: implications for clinical trials of psychotropic agents in dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Behavior Therapy; Data Interpretat | 2004 |
Early polyneuropharmacologic intervention in brain injury agitation.
Topics: Adolescent; Adult; Amantadine; Antipsychotic Agents; Brain Injuries; Dextroamphetamine; Drug Adminis | 2002 |
[Pharmacotherapy to control agitation in patients with cognitive deficits].
Topics: Aged; Aphasia; Cerebral Infarction; Drug Therapy, Combination; Female; Humans; Psychomotor Agitation | 1990 |
Reply to Risse and Barnes: Pharmacologic treatment of agitation associated with dementia.
Topics: Dementia; Humans; Psychomotor Agitation; Trazodone | 1988 |